{"id":7846,"date":"2024-12-04T00:27:43","date_gmt":"2024-12-04T00:27:43","guid":{"rendered":"https:\/\/els-solutions.com\/cms\/dev\/?p=7846"},"modified":"2024-12-04T00:27:43","modified_gmt":"2024-12-04T00:27:43","slug":"progress-clinical-research-brazil-anvisa","status":"publish","type":"post","link":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/","title":{"rendered":"Progress in Clinical Research in Brazil: New ANVISA Regulations"},"content":{"rendered":"<\/p>\n<p style=\"text-align: center;\">The updating of ANVISA&#8217;s regulatory framework for clinical research represents a strategic opportunity for companies wishing to boost drug development in Brazil. The reduction in bureaucracy and the possibility of anticipating the import of drugs for research are advances that not only speed up studies, but also bring predictability and efficiency to sponsors and research centers.<\/p>\n<p style=\"text-align: center;\">At ELS, we are prepared to help our clients take full advantage of these changes. Our ELSApdi service is designed to facilitate everything from the submission of ongoing data to ANVISA to the management of clinical trial import and monitoring processes, ensuring agility and compliance with the new regulatory standards.<\/p>\n<p style=\"text-align: center;\">With clearer definitions of risk categories and study phases, ANVISA&#8217;s modernization strengthens Brazil&#8217;s competitiveness on the global stage. This creates a favorable environment for integrating the conduct of clinical research with obtaining international certifications, such as EU GMP, increasing the relevance of Brazilian products in foreign markets. At ELS, we see this evolution as an opportunity to consolidate strategic partnerships and offer solutions that add value at all stages of clinical and regulatory development.<\/p>\n<p style=\"text-align: center;\">If you need more information on regulatory issues, ELS can certainly help.<\/p>\n<p style=\"text-align: center;\"><span class=\" author-d-iz88z86z86za0dz67zz78zz78zz74zz68zjz80zz71z9iz90z9z84zmz66zz71znz68znz69zz87z3z89zhz65zz89zybhz84zz79zkwtz79zsz76zdz122zjz80z7\">Please do not hesitate to c<\/span>ontact your <a href=\"https:\/\/els-solutions.com\/en\/where-are-we\/\" target=\"_blank\" rel=\"noopener\">local ELS consultant<\/a>\u00a0or via email<strong> info@elssolutions.pt<\/strong><\/p>\n<p>\n","protected":false},"excerpt":{"rendered":"<p>This update aims to make Brazil an even more attractive environment for investment in clinical research and to strengthen the health innovation ecosystem.<\/p>\n","protected":false},"author":9,"featured_media":7847,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_joinchat":[],"footnotes":""},"categories":[54,61],"tags":[62],"class_list":["post-7846","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general","category-news","tag-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Progress in Clinical Research in Brazil: New ANVISA Regulations<\/title>\n<meta name=\"description\" content=\"ANVISA has just approved a new regulatory framework for clinical research in Brazil, with the aim of modernizing and simplifying drug development processes in the country. This update aims to make Brazil an even more attractive environment for investment in clinical research and to strengthen the health innovation ecosystem.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"List of medicines with suspended exports updated\" \/>\n<meta property=\"og:description\" content=\"They update the list of medicines with suspended exports in order to normalize the supply of critical and exceptional products.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/\" \/>\n<meta property=\"og:site_name\" content=\"ELS Group - Accelerating Innovation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/els.solutions\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-04T00:27:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/09\/ELS-Solutions-updating-medicines-supended-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marketing ELS\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marketing ELS\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/\"},\"author\":{\"name\":\"Marketing ELS\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3\"},\"headline\":\"Progress in Clinical Research in Brazil: New ANVISA Regulations\",\"datePublished\":\"2024-12-04T00:27:43+00:00\",\"dateModified\":\"2024-12-04T00:27:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/\"},\"wordCount\":940,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/12\/Anvisa-Pesquisa-clinica-1.png\",\"keywords\":[\"News\"],\"articleSection\":[\"General\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/\",\"url\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/\",\"name\":\"Progress in Clinical Research in Brazil: New ANVISA Regulations\",\"isPartOf\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/12\/Anvisa-Pesquisa-clinica-1.png\",\"datePublished\":\"2024-12-04T00:27:43+00:00\",\"dateModified\":\"2024-12-04T00:27:43+00:00\",\"description\":\"ANVISA has just approved a new regulatory framework for clinical research in Brazil, with the aim of modernizing and simplifying drug development processes in the country. This update aims to make Brazil an even more attractive environment for investment in clinical research and to strengthen the health innovation ecosystem.\",\"breadcrumb\":{\"@id\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#primaryimage\",\"url\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/12\/Anvisa-Pesquisa-clinica-1.png\",\"contentUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/12\/Anvisa-Pesquisa-clinica-1.png\",\"width\":1200,\"height\":600,\"caption\":\"Progress in Clinical Research in Brazil: New ANVISA Regulations\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/els-solutions.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Progress in Clinical Research in Brazil: New ANVISA Regulations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/els-solutions.com\/en\/#website\",\"url\":\"https:\/\/els-solutions.com\/en\/\",\"name\":\"ELS Group - Accelerating Innovation\",\"description\":\"Assessoria estrat\u00e9gia para a Ind\u00fastria Farmac\u00eautica\",\"publisher\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/els-solutions.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/els-solutions.com\/en\/#organization\",\"name\":\"ELS Group - Accelerating Innovation\",\"url\":\"https:\/\/els-solutions.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png\",\"contentUrl\":\"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png\",\"width\":2226,\"height\":1080,\"caption\":\"ELS Group - Accelerating Innovation\"},\"image\":{\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/els.solutions\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3\",\"name\":\"Marketing ELS\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/els-solutions.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g\",\"caption\":\"Marketing ELS\"},\"sameAs\":[\"https:\/\/els-solutions.com\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Progress in Clinical Research in Brazil: New ANVISA Regulations","description":"ANVISA has just approved a new regulatory framework for clinical research in Brazil, with the aim of modernizing and simplifying drug development processes in the country. This update aims to make Brazil an even more attractive environment for investment in clinical research and to strengthen the health innovation ecosystem.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/","og_locale":"en_US","og_type":"article","og_title":"List of medicines with suspended exports updated","og_description":"They update the list of medicines with suspended exports in order to normalize the supply of critical and exceptional products.","og_url":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/","og_site_name":"ELS Group - Accelerating Innovation","article_publisher":"https:\/\/www.facebook.com\/els.solutions\/","article_published_time":"2024-12-04T00:27:43+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/09\/ELS-Solutions-updating-medicines-supended-1.jpg","type":"image\/jpeg"}],"author":"Marketing ELS","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Marketing ELS","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#article","isPartOf":{"@id":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/"},"author":{"name":"Marketing ELS","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3"},"headline":"Progress in Clinical Research in Brazil: New ANVISA Regulations","datePublished":"2024-12-04T00:27:43+00:00","dateModified":"2024-12-04T00:27:43+00:00","mainEntityOfPage":{"@id":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/"},"wordCount":940,"commentCount":0,"publisher":{"@id":"https:\/\/els-solutions.com\/en\/#organization"},"image":{"@id":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#primaryimage"},"thumbnailUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/12\/Anvisa-Pesquisa-clinica-1.png","keywords":["News"],"articleSection":["General","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/","url":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/","name":"Progress in Clinical Research in Brazil: New ANVISA Regulations","isPartOf":{"@id":"https:\/\/els-solutions.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#primaryimage"},"image":{"@id":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#primaryimage"},"thumbnailUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/12\/Anvisa-Pesquisa-clinica-1.png","datePublished":"2024-12-04T00:27:43+00:00","dateModified":"2024-12-04T00:27:43+00:00","description":"ANVISA has just approved a new regulatory framework for clinical research in Brazil, with the aim of modernizing and simplifying drug development processes in the country. This update aims to make Brazil an even more attractive environment for investment in clinical research and to strengthen the health innovation ecosystem.","breadcrumb":{"@id":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#primaryimage","url":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/12\/Anvisa-Pesquisa-clinica-1.png","contentUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2024\/12\/Anvisa-Pesquisa-clinica-1.png","width":1200,"height":600,"caption":"Progress in Clinical Research in Brazil: New ANVISA Regulations"},{"@type":"BreadcrumbList","@id":"https:\/\/els-solutions.com\/en\/progress-clinical-research-brazil-anvisa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/els-solutions.com\/en\/"},{"@type":"ListItem","position":2,"name":"Progress in Clinical Research in Brazil: New ANVISA Regulations"}]},{"@type":"WebSite","@id":"https:\/\/els-solutions.com\/en\/#website","url":"https:\/\/els-solutions.com\/en\/","name":"ELS Group - Accelerating Innovation","description":"Assessoria estrat\u00e9gia para a Ind\u00fastria Farmac\u00eautica","publisher":{"@id":"https:\/\/els-solutions.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/els-solutions.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/els-solutions.com\/en\/#organization","name":"ELS Group - Accelerating Innovation","url":"https:\/\/els-solutions.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png","contentUrl":"https:\/\/els-solutions.com\/cms\/wp-content\/uploads\/2023\/08\/ELS-NewLogo-ColorBlack-1-e1691153715735.png","width":2226,"height":1080,"caption":"ELS Group - Accelerating Innovation"},"image":{"@id":"https:\/\/els-solutions.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/els.solutions\/"]},{"@type":"Person","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/person\/9fb8dae537039679cfc537a000df6ca3","name":"Marketing ELS","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/els-solutions.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b785df1d10c9806cc43fcea2dbf585b96a8761ff697010979d603fc5b7a9ca7b?s=96&d=mm&r=g","caption":"Marketing ELS"},"sameAs":["https:\/\/els-solutions.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts\/7846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/comments?post=7846"}],"version-history":[{"count":1,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts\/7846\/revisions"}],"predecessor-version":[{"id":7850,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/posts\/7846\/revisions\/7850"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/media\/7847"}],"wp:attachment":[{"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/media?parent=7846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/categories?post=7846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/els-solutions.com\/en\/wp-json\/wp\/v2\/tags?post=7846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}